These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 3157927)

  • 21. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
    St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
    Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
    Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
    Redding TW; Coy DH; Schally AV
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1273-6. PubMed ID: 6803239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
    Szepeshazi K; Korkut E; Szende B; Lapis K; Schally AV
    Prostate; 1991; 18(3):255-70. PubMed ID: 2020621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D; Dubé D; Bélanger A; Labrie F
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
    Pinski J; Yano T; Miller G; Schally AV
    Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous phosphorylation in Dunning prostate tumors of rats treated with LH-RH analogues.
    Cehovic G; Redding TW; Hierowski MT; Schally AV
    Prostate; 1984; 5(6):605-11. PubMed ID: 6238290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats.
    Karashima T; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2329-33. PubMed ID: 2965391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
    Letsch M; Schally AV; Stangelberger A; Groot K; Varga JL
    Eur J Cancer; 2004 Feb; 40(3):436-44. PubMed ID: 14746863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.